DNAJC7 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function analysis of the DNAJC7 gene in the K-562 chronic myelogenous leukemia (CML) cell line. Generated via CRISPR/Cas9-mediated gene disruption, this polyclonal pool preserves genetic heterogeneity, minimizing clonal artifacts and enabling robust functional genomics studies. The model is well-suited for exploring DNAJC7??s role in chaperone-mediated protein quality control, steroid hormone receptor signaling, and Hippo pathway regulation.
The K-562 cell line, derived from a Philadelphia chromosome-positive CML patient in blast crisis, is a widely used model for leukemia and hematopoietic differentiation research. It harbors the BCR-ABL1 fusion oncogene, which drives constitutive tyrosine kinase activity and oncogenic addiction, making it particularly relevant for investigating Hsp90 chaperone network dependencies in cancer.
DNAJC7 encodes a co-chaperone that orchestrates Hsp90 chaperone cycle progression by forming complexes with Hsp70 and STIP1 (HOP) to facilitate client loading. It is essential for maturation of steroid hormone receptors (glucocorticoid receptor NR3C1, androgen receptor AR) and for stabilizing the Hippo pathway kinase MST1 (STK4). DNAJC7 expression is induced by HSF1 under stress. Interactions with MST1 prevent its degradation, promoting phosphorylation of SAV1 and downstream YAP/TAZ signaling. Loss of DNAJC7 disrupts client maturation, leading to impaired MST1 activity, deregulated YAP/TAZ, and potential proteotoxic stress.
In the K-562 background, DNAJC7 knockout enables dissection of its putative tumor-suppressive functions within the BCR-ABL1-driven oncogenic network. Given Hsp90??s role in stabilizing BCR-ABL1, disruption of the co-chaperone network can alter proteotoxic stress responses, apoptosis, and sensitivity to Hsp90 inhibitors like geldanamycin. This polyclonal model permits evaluation of glucocorticoid receptor reporter activity, Hippo pathway output, and ciliogenesis defects in a leukemia-relevant setting.
The product supports diverse applications: Western blotting and RT-qPCR for target validation, co-immunoprecipitation for chaperone/client mapping, flow cytometry for apoptosis and cell cycle analysis, glucocorticoid receptor reporter assays, RNA-seq profiling, and Hsp90 inhibitor screening. DNAJC7 Knockout K-562 Polyclonal Cells offer a versatile platform for studying chaperone biology, leukemia mechanisms, and Hippo signaling. For additional information, contact Ascent Research.
